PUBLISHER: IMARC | PRODUCT CODE: 1347411
PUBLISHER: IMARC | PRODUCT CODE: 1347411
The global stem cell banking market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.
Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy. It is the process of extracting, freezing and storing stem cells for potential future use. Some of the sources through which stem cells are obtained include embryo, umbilical cord, cord blood, placenta and bone marrow. These cells are used for treating a number of different diseases including diabetes, thalassemia, leukemia, sickle cell anemia and cardiac diseases. Moreover, they are also employed for generating platelets, red blood cells and white blood cells. The potential of stem cells to regenerate has led to their applications in tissue engineering, gene therapy and regenerative medicines.
While the average human life expectancy has increased owing to the advancements in medical science, human aging is still associated with several diseases. Thus, the elevating count of geriatric population will drive the demand for stem cell therapy in the coming years.
Regulatory authorities as well as non-governmental organizations (NGO), across both developed and emerging regions, are taking initiatives for instilling awareness amongst consumers about the therapeutic potentials of stem cells, thereby influencing the stem cell banking market growth.
Increasing fertility rates has led to a rise in the number of children across the globe. This offers lucrative opportunities for preserving the umbilical cord of infants which contains hematopoietic (blood) stem cells.
Some of the other factors which are catalyzing the growth of the market include escalating disposable incomes, increasing approval of clinical trials in stem cell research, growing prevalence of chronic diseases and technological advancements.
IMARC Group provides an analysis of the key trends in each segment of the global stem cell banking market report, along with forecasts at the global and regional levels from 2023-2028. Our report has categorized the market based on product type, service type, bank type, utilization and application.
Adult Stem Cells
Human Embryonic Cells
IPS Cells
On the basis of product types, the market has been segmented as adult stem cells, human embryonic cells and IPS cells. Presently, adult stem cells account for the majority of the market share as they help in repairing damaged tissues via cell division. In addition to this, adult stem cells offer advantages like ease of harvesting, high acceptance in the human body and effectiveness in tissue generation.
Sample Preservation and Storage
Sample Analysis
Sample Processing
Sample Collection and Transportation
Based on service types, the market has been segmented as sample preservation and storage, sample analysis, sample processing, and sample collection and transportation.
Private
Public
Based on the bank type, the market has been segregated as private and public stem cell banks. Private stem cell banks currently dominate the market, holding the largest share.
Used
Unused
Based on the utilization, the market has been segregated as used and unused.
Personalized Banking Applications
Research Applications
Clinical Applications
On the basis of application, the market has been segmented as personalized banking applications, research applications and clinical applications.
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
On a geographical front, North America enjoys the leading position in the global stem cell banking market on account of advancements in medical infrastructure and availability of federal funding for stem cell research. Other regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
CBR Systems Inc.
China Cord Blood Corporation
Cordlife
Cordvida
Cryo-Cell International, Inc.
Cryo-Save AG (A Group of Esperite)
Cryoviva India
Lifecell
Smart Cells International Ltd
Viacord